Last reviewed · How we verify
Experimental drug: Ondansetron
Ondansetron blocks serotonin 5-HT3 receptors on chemoreceptor trigger zone and vagal afferent nerves to prevent nausea and vomiting.
Ondansetron blocks serotonin 5-HT3 receptors on chemoreceptor trigger zone and vagal afferent nerves to prevent nausea and vomiting. Used for Chemotherapy-induced nausea and vomiting (CINV), Postoperative nausea and vomiting (PONV), Radiation-induced nausea and vomiting.
At a glance
| Generic name | Experimental drug: Ondansetron |
|---|---|
| Sponsor | CCTU |
| Drug class | 5-HT3 receptor antagonist |
| Target | 5-HT3 receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology, Gastroenterology, Anesthesia |
| Phase | Phase 3 |
Mechanism of action
Ondansetron is a selective antagonist of serotonin 5-HT3 receptors, which are located in the chemoreceptor trigger zone and on vagal afferent fibers in the gastrointestinal tract. By blocking these receptors, it prevents the transmission of emetic signals to the vomiting center in the brainstem. This mechanism makes it particularly effective for chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea and vomiting (PONV).
Approved indications
- Chemotherapy-induced nausea and vomiting (CINV)
- Postoperative nausea and vomiting (PONV)
- Radiation-induced nausea and vomiting
Common side effects
- Headache
- Constipation
- Diarrhea
- Fatigue
- Dizziness
- QT prolongation
Key clinical trials
- Peritoneal Lavage Using Saline or Saline With Ondansetron for Pain Control After Laparoscopic Cholecystectomy (PHASE4)
- Electroacupuncture for Chemotherapy-Induced GI Symptom Clusters in Breast Cancer (PHASE3)
- the Efficacy and Safety of Oliceridine Fumarate Injection for Acute Pain After Abdominal Surgery (PHASE4)
- Effect of Kinesiotape on Emesis in Pregnant Women (NA)
- Accelerated Recovery Following Opioid-free Anaesthesia in Supratentorial Craniotomy (NA)
- the Efficacy and Safety of Ondansetron Oral Soluble Pellicles (PHASE3)
- Endocrinological Changes Due to Pre-medications of Chemotherapy in Patients With Breast Cancer (NA)
- Proof of Concept Study to Evaluate the Safety Profile of Plitidepsin in Patients With COVID-19 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Experimental drug: Ondansetron CI brief — competitive landscape report
- Experimental drug: Ondansetron updates RSS · CI watch RSS
- CCTU portfolio CI